The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Proteome-based plasma biomarkers for Alzheimer's disease
Open accessAbstract
Alzheimer's disease is a common and devastating disease for which there is no readily available biomarker to aid diagnosis or to monitor disease progression. Biomarkers have been sought in CSF but no previous study has used two-dimensional gel electrophoresis coupled with mass spectrometry to seek biomarkers in peripheral tissue. We performed a case-control study of plasma using this proteomics approach to identify proteins that differ in the disease state relative to aged controls. For discovery-phase proteomics analysis, 50 people with Alzheimer's dementia were recruited through secondary services and 50 normal elderly controls through primary care. For validation purposes a total of 511 subjects with Alzheimer's disease and other neurodegenerative diseases and normal elderly controls were examined. Image analysis of the protein distribution of the gels alone identifies disease cases with 56% sensitivity and 80% specificity. Mass spectrometric analysis of the changes observed in two-dimensional electrophoresis identified a number of proteins previously implicated in the disease pathology, including complement factor H (CFH) precursor and alpha-2-macroglobulin (alpha-2M). Using semi-quantitative immunoblotting, the elevation of CFH and alpha-2M was shown to be specific for Alzheimer's disease and to correlate with disease severity although alternative assays would be necessary to improve sensitivity and specificity. These findings suggest that blood may be a rich source for biomarkers of Alzheimer's disease and that CFH, together with other proteins such as alpha-2M may be a specific markers of this illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 8×
“There is a wide variation in normal plasma levels of CFH (Esparza-Gordillo et al., 2004) and recently polymorphic variation in the gene encoding CFH has been strongly associated with age-related macular degeneration (AMD) (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005).”
BackgroundInfluentialComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 8×
“There is a wide variation in normal plasma levels of CFH (Esparza-Gordillo et al., 2004) and recently polymorphic variation in the gene encoding CFH has been strongly associated with age-related macular degeneration (AMD) (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005).”
BackgroundInfluentialHageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 8×
“There is a wide variation in normal plasma levels of CFH (Esparza-Gordillo et al., 2004) and recently polymorphic variation in the gene encoding CFH has been strongly associated with age-related macular degeneration (AMD) (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005).”
InfluentialCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Mullins, R. F., Russell, S. R., Anderson, D. H., & Hageman, G. S. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.7.835 · Cited by 937
The human complement factor H: functional roles, genetic variations and disease associations
RODRIGUEZDECORDOBA, S., ESPARZAGORDILLO, J., GOICOECHEADEJORGE, E., LOPEZTRASCASA, M., & SANCHEZCORRAL, P. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.02.005 · Cited by 574
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., & Berger, M. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80737-n · Cited by 483
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192203399 · Cited by 447
Cited by
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Self-citationLantero Rodriguez, J., Karikari, T. K., Suárez-Calvet, M., Troakes, C., King, A., Emersic, A., Aarsland, D., Hye, A., Zetterberg, H., Blennow, K., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02195-x · Cited by 350
Self-citationEvidence of altered phosphatidylcholine metabolism in Alzheimer's disease
Whiley, L., Sen, A., Heaton, J., Proitsi, P., García-Gómez, D., Leung, R., Smith, N., Thambisetty, M., Kloszewska, I., Mecocci, P., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.001 · Cited by 340
Self-citationU1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease
Bai, B., Hales, C. M., Chen, P.-C., Gozal, Y., Dammer, E. B., Fritz, J. J., Wang, X., Xia, Q., Duong, D. M., Street, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310249110 · Cited by 335
“Proc Natl Acad Sci USA 82(12):4245–4249.”
The future of blood‐based biomarkers for Alzheimer's disease
Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 313
Self-citationPersonalized protein corona on nanoparticles and its clinical implications
Corbo, C., Molinaro, R., Tabatabaei, M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Biomaterials Science · doi:10.1039/c6bm00921b · Cited by 308
Plasma proteomic profiles predict future dementia in healthy adults
Guo, Y., You, J., Zhang, Y., Liu, W.-S., Huang, Y.-Y., Zhang, Y.-R., Zhang, W., Dong, Q., Feng, J.-F., Cheng, W., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00565-0 · Cited by 293
MicroRNAs in Plasma and Cerebrospinal Fluid as Potential Markers for Alzheimer's Disease
Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-130932 · Cited by 256
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223
“All subjects were assessed with a standardized assessment protocol including an informant interview for diagnosis and cognitive assessment such as the Mini-Mental State Examination (MMSE) together with standardized assessment of function, behavior, and dementia severity as previously reported [13,19,20].”
Self-citationPlasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“Another study using explorative proteomics technology identified AD-associated changes in the plasma levels of complement factor H and a2-macroglobulin (Hye et al. 2006).”
BackgroundLarge-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk
Walker, K. A., Chen, J., Zhang, J., Fornage, M., Yang, Y., Zhou, L., Grams, M. E., Tin, A., Daya, N., Hoogeveen, R. C., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00064-0 · Cited by 212
Gezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, Ö. S., Atasoy, İ. L., Alaylıoğlu, M., Önal, B., Gürvit, H., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130497 · Cited by 188
Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
Self-citationAshton, N. J., Leuzy, A., Lim, Y. M., Troakes, C., Hortobágyi, T., Höglund, K., Aarsland, D., Lovestone, S., Schöll, M., Blennow, K., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0649-3 · Cited by 172
Self-citationAshton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Association of social and cognitive impairment and biomarkers in autism spectrum disorders
Alabdali, A., Al-Ayadhi, L., & El-Ansary, A. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-4 · Cited by 117
“In humans, about 500 mL of CSF is absorbed into the blood daily, making blood a suitable source of neurodegenerative or neurodevelopmental disease biomarkers [34].”
BackgroundBiomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
Lue, L.-F., Sabbagh, M. N., Chiu, M.-J., Jing, N., Snyder, N. L., Schmitz, C., Guerra, A., Belden, C. M., Chen, T.-F., Yang, C.-C., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00226 · Cited by 105
“To meet the need of higher detection sensitivity, new technologies have been developed (Hye et al., 2006; Yang et al., 2011; Chang et al., 2012; Irwin et al., 2012; Mattsson et al., 2013).”
BackgroundAlabdali, A., Al-Ayadhi, L., & El-Ansary, A. (2014) · Behavioral and Brain Functions · doi:10.1186/1744-9081-10-14 · Cited by 101
“In humans, approximately 500 ml of CSF is absorbed into the blood daily, making blood a suitable source of biomarkers of neurodegenerative or neurodevelopmental diseases [14].”
BackgroundPlasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
Kiddle, S. J., Thambisetty, M., Simmons, A., Riddoch-Contreras, J., Hye, A., Westman, E., Pike, I., Ward, M., Johnston, C., Lupton, M. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044260 · Cited by 100
“The identification of blood-based biomarkers associated with AD diagnosis [6–9] or distinct endophenotypes of AD pathology such as brain atrophy [10–12], hippocampal metabolite abnormalities [13] and amyloid burden [14], have previously been reported.”
Self-citationRoubroeks, J. A. Y., Smith, A. R., Smith, R. G., Pishva, E., Ibrahim, Z., Sattlecker, M., Hannon, E. J., Kłoszewska, I., Mecocci, P., Soininen, H., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.023 · Cited by 82
Self-citationHan, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Cullen, N. C., Mälarstig, A. N., Stomrud, E., Hansson, O., & Mattsson-Carlgren, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-81705-7 · Cited by 62
Du, L., Zhang, J., Liu, F., Wang, H., Guo, L., Han, J., & Disease Neuroimaging Initiative, T. A. (2021) · Medical Image Analysis · doi:10.1016/j.media.2021.102003 · Cited by 56
Ma, L., Chen, J., Wang, R., Han, Y., Zhang, J., Dong, W., Zhang, X., Wu, Y., & Zhao, Z. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.011 · Cited by 53
Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression
Yang, H., Lyutvinskiy, Y., Herukka, S.-K., Soininen, H., Rutishauser, D., & Zubarev, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132102 · Cited by 52
Urinary metabolic phenotyping for Alzheimer’s disease
Kurbatova, N., Garg, M., Whiley, L., Chekmeneva, E., Jiménez, B., Gómez-Romero, M., Pearce, J., Kimhofer, T., D’Hondt, E., Soininen, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78031-9 · Cited by 44
Self-citationEvaluating the Alzheimer’s disease data landscape
Birkenbihl, C., Salimi, Y., Domingo‐Fernándéz, D., Lovestone, S., AddNeuroMed consortium, Fröhlich, H., Hofmann‐Apitius, M., Initiative, T. J. A. D. N., & Initiative, A. T. A. D. N. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12102 · Cited by 37
Self-citationProgress and challenges in the diagnosis of dementia: a critical review
Paraskevaidi, M., Martin-Hirsch, P. L., & Martin, F. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00007 · Cited by 31
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
Ahmad, S., Milan, M. D. C., Hansson, O., Demirkan, A., Agustin, R., Sáez, M. E., Giagtzoglou, N., Cabrera-Socorro, A., Bakker, M. H. M., Ramirez, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65038-5 · Cited by 31
“The levels of CSF AD-related biomarkers (Aβ42, total and phosphorylated tau [t-Tau and p-Tau181]) were analyzed at Amsterdam UMC as part of the routine diagnostic procedure using commercially available kits (Innotest Aβ(1-42), total Tau, phospho-Tau(181 P); Fujirebio, Ghent, Belgium)10,24.”
MethodKang, S., Jeong, H., Baek, J.-H., Lee, S.-J., Han, S.-H., Cho, H. J., Kim, H., Hong, H. S., Kim, Y. H., Yi, E. C., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160025 · Cited by 30
Jayasena, T., Poljak, A., Braidy, N., Smythe, G., Raftery, M., Hill, M., Brodaty, H., Trollor, J., Kochan, N., & Sachdev, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116092 · Cited by 30
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Hudd, F., Shiel, A., Harris, M., Bowdler, P., McCann, B., Tsivos, D., Wearn, A., Knight, M., Kauppinen, R., Coulthard, E., et al. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180879 · Cited by 26
The pathway to secondary prevention of Alzheimer's disease
McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12069 · Cited by 20
Killick, R., Hughes, T. R., Morgan, B. P., & Lovestone, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.008 · Cited by 17
Self-citationYakushev, I., Bartenstein, P., Siessmeier, T., Hiemke, C., Scheurich, A., Lotz, J., Fellgiebel, A., & Müller, M. J. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000320206 · Cited by 9
Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer’s disease
Frick, E. A., Emilsson, V., Jonmundsson, T., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A., Boada, M., et al. (2023) · doi:10.1101/2023.11.08.23298251 · Cited by 3
Metadata
- Authors
- Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F., Tabrizi, S. J., Banner, S., Shaw, C. E., Foy, C., Poppe, M., Archer, N., Hamilton, G., Powell, J., Brown, R. G., Sham, P., Ward, M., & Lovestone, S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-11-01
- Volume
- 129
- Issue
- 11
- Pages
- 3042-3050
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2047219385
- Cited by
- 464
- References
- 39
- FWCI
- 15.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.